<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080298</url>
  </required_header>
  <id_info>
    <org_study_id>BP101-SD01</org_study_id>
    <nct_id>NCT03080298</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire</brief_title>
  <official_title>International, Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2a Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivix LLX</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ivix LLX</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is study of the efficacy, safety and pharmacokinetics of BP101 compared to placebo in
      patients with a decrease or loss of sexual desire.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2016</start_date>
  <completion_date type="Actual">July 25, 2017</completion_date>
  <primary_completion_date type="Actual">April 4, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Desire domain score in the Female Sexual Function Index</measure>
    <time_frame>28 days (4 weeks) of treatment</time_frame>
    <description>Change in the Desire domain score in the Female Sexual Function Index (FSFI) after 28 days (4 weeks) of treatment compared with the baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Item 13 score in the Female Sexual Distress Scale-Revised</measure>
    <time_frame>28 days (4 weeks) of treatment</time_frame>
    <description>Change of Item 13 score in the Female Sexual Distress Scale-Revised (FSDS-R) after 28 days (4 weeks) of treatment compared with the baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Desire domain in the Female Sexual Function Index</measure>
    <time_frame>28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up</time_frame>
    <description>Change of the Desire domain in the Female Sexual Function Index (FSFI) after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Item 13 score in the Female Sexual Distress Scale-Revised</measure>
    <time_frame>28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up</time_frame>
    <description>Change of Item 13 score in the Female Sexual Distress Scale-Revised (FSDS-R) after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfying sexual events</measure>
    <time_frame>28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up</time_frame>
    <description>Change in the number of satisfying sexual events (SSEs) in proportion to the 28 day period after 28 days (4 weeks) of the therapy and after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total score of the Female Sexual Function Index</measure>
    <time_frame>28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up</time_frame>
    <description>Change of the total score of the Female Sexual Function Index (FSFI) after 28 days (4 weeks) of the therapy and after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total score of the Female Sexual Distress Scale-Revised</measure>
    <time_frame>28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up</time_frame>
    <description>Change of total score of the Female Sexual Distress Scale-Revised (FSDS-R) after 28 days (4 weeks) of the therapy and after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The sexual function according to the Female Sexual Function questionnaire</measure>
    <time_frame>28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up</time_frame>
    <description>Change of the sexual function according to the Female Sexual Function questionnaire (FSF) after 28 days (4 weeks) of the therapy and after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient's assessment of efficacy of the therapy according to the Patient Global Impression of Improvement</measure>
    <time_frame>28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up</time_frame>
    <description>The patient's assessment of efficacy of the therapy according to the Patient Global Impression of Improvement (PGI-I) after 28 days (4 weeks) of the therapy and after 28 days (4 weeks) and 56 days (8 weeks) of the follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up</time_frame>
    <description>Frequency of adverse events reporting, including serious adverse events, in treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Hypoactive Sexual Desire Disorder (HSDD)</condition>
  <arm_group>
    <arm_group_label>Treatment with BP101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BP101</intervention_name>
    <arm_group_label>Treatment with BP101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Treatment with placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 21 or older, who have signed informed concent, with a regular menstrual
             cycle (STRAW stages -5 to -3 (see Annex 7)).

          -  The level of follicle-stimulating hormone (FSH) is not more than 25
             milli-International unit per ml (mIU/ml) according to the screening values.

          -  Decrease or loss of sexual desire (ICD-10 code: F-52.0) corresponding to the
             hypoactive sexual desire disorder (HSDD) diagnosed according to Diagnostic and
             Statistical Manual of Mental Disorders, 4th Edition (DSM4), criteria.

          -  Current HSDD episode lasting not less than 24 weeks.

          -  Patients with secondary female sexual arousal disorder (FSAD) and/or female orgasmic
             disorder (FOD) will be eligible only if the HSDD developed before the FSAD and/or FOD
             and the HSDD has a more significant impact on the patient's quality of life.

          -  Not less than 15 scores according to the FSDS-R (Distress) Total Score.

          -  Stable monogamous relationship with one sexually active male sexual partner lasting at
             least a year. The partner is physically available not less than 50% of time during a
             month.

          -  Consent to attempt to have a sexual intercourse at least twice a month, if she has a
             desire.

          -  Consent to complete a diary every day during the screening period and assessment of
             the baseline state (in this period diary records must cover ≥80% days), during the
             therapy and subsequent follow-up.

          -  Consent to use adequate methods of contraception throughout the study.

        Exclusion Criteria:

          -  Any prohibited treatments.

          -  Other mental disorders or psychiatric diseases.

          -  Score ≥ 20 according to the Beck Depression Inventory during the screening. Patients
             with 16 to 19 scores according to Beck's inventory may be included in the study
             unless, in the investigator's opinion, an actual depressive disorder is observed in
             the patient.

          -  Inflammatory diseases of pelvic organs, infections of the genitourinary system,
             cervicitis, interstitial cystitis, vulvodynia or severe atrophy of the vaginal
             epithelium.

          -  Surgical interventions (other than cosmetic surgeries) on reproductive organs in past
             medical history (ovariectomy, hysterectomy, obvious scars from childbirth-related
             perineal stitches, etc).

          -  Pregnant and nursing women or non-lactating women during the first 12 months after
             childbirth.

          -  Consumption of more than 5 portions of alcoholic drinks per week or alcohol addiction,
             drug addiction or drug abuse in the past. One portion of an alcoholic drink means 360
             ml of beer, 120 ml of wine or 30 ml of a strong alcoholic drink.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniil G Nemenov, MD</last_name>
    <role>Study Director</role>
    <affiliation>IVIX Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Psychiatric Hospital</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.M. Bekhterev Republic Clinical Psychiatric Hospital</name>
      <address>
        <city>Kazan'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;People's Friendship University of Russia&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Research Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.A. Alexeev Moscow Psychiatric Clinical Hospital #1</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Psychiatry Hospital №1</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orenburg Regional Clinical Psychiatric Hospital #1</name>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrKli Hospital LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Engels Psycyatric hospital</name>
      <address>
        <city>Saratov Oblast</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Psychiatric Hospital of St. Sofia</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic &quot;Hundred Years&quot;</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clinical Psychiatric Hospital</name>
      <address>
        <city>Yaroslavl'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

